Skip to main content
Signal8

enVVeno Medical Corp (NVNO)

enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

enVVeno Medical Corporation logo

enVVeno Medical Corporation

NASDAQ:NVNOHealthcare
-2.94%$5.77
CLOSED
AH$5.77+0.00%vs close
Mkt Cap$4.01M
EV-
Float691K
O/S695K
VOL11K sh
$ Vol$65K
RVOL0.34×
Inst Own12.6%
SI3.5%
Net Cash/Sh-
Dilution
enVVeno Medical Corporation logoNASDAQ:NVNOClosed$5.77-2.94%
FormDescription
13G/A
Beneficial Ownership Report (Amended)
DEFA14A
Additional Proxy Materials
DEF 14A
Definitive Proxy Statement
10-Q
13D/A
4
Statement of Changes in Beneficial Ownership
144
Notice of Proposed Sale of Securities
S-3
13G/A
Beneficial Ownership Report (Amended)
10-Q
8-K
7.01,9.01
4
Statement of Changes in Beneficial Ownership
144
Notice of Proposed Sale of Securities
13G/A
Beneficial Ownership Report (Amended)
13G/A
Beneficial Ownership Report (Amended)
10-Q
Quarterly Report
8-K
2.02,7.01,8.01,9.01
S-8
SEC Filing
10-K
Annual Report
4
Statement of Changes in Beneficial Ownership
144
Notice of Proposed Sale of Securities
13D
Beneficial Ownership Report (Active)
13D
Beneficial Ownership Report (Active)
13G/A
Beneficial Ownership Report (Amended)
13G
Beneficial Ownership Report

1-25 of 416

…

Recent SEC filings with analysis

    enVVeno Medical Corp (NVNO) SEC Filings: 10-K, 10-Q, 8-K | Signal8